drugset / Trial / NCT01263119

A Study of LY2216684 and Warfarin in Healthy Subjects

NCT01263119

Phase 1 Completed 18 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine how warfarin might affect LY2216684 and how giving LY2216684 might affect warfarin in the body. Information about any side effects that may occur will also be collected.

Timeline

Start
2010-12
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Warfarin Small molecule 10 mg Oral
Subject edivoxetine Small molecule 18 mg Oral